Mitsubishi UFJ Asset Management Co. Ltd. Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Mitsubishi UFJ Asset Management Co. Ltd. trimmed its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 58.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,155 shares of the biotechnology company’s stock after selling 8,576 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Arrowhead Pharmaceuticals were worth $417,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Arrowhead Pharmaceuticals by 3.3% during the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock valued at $553,077,000 after acquiring an additional 510,798 shares during the period. Avoro Capital Advisors LLC grew its stake in Arrowhead Pharmaceuticals by 2.8% during the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock worth $375,941,000 after buying an additional 300,000 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in Arrowhead Pharmaceuticals by 3,142.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after buying an additional 2,017,489 shares during the period. Goldman Sachs Group Inc. grew its stake in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares during the period. Finally, Baker BROS. Advisors LP grew its stake in Arrowhead Pharmaceuticals by 77.9% during the third quarter. Baker BROS. Advisors LP now owns 1,670,762 shares of the biotechnology company’s stock worth $57,625,000 after buying an additional 731,588 shares during the period. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Trading Down 1.5%

Shares of ARWR opened at $77.88 on Thursday. The company has a market capitalization of $10.97 billion, a P/E ratio of -36.22 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a one year low of $14.30 and a one year high of $80.67. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The stock has a 50-day moving average price of $65.40 and a 200 day moving average price of $61.45.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. The firm had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.Arrowhead Pharmaceuticals’s revenue for the quarter was down 86.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.75 earnings per share. Sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.98 EPS for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of the stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total transaction of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This represents a 4.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer owned 162,905 shares in the company, valued at $11,623,271.75. This trade represents a 7.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 33,095 shares of company stock valued at $2,326,228 in the last three months. 3.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ARWR shares. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $78.00 to $100.00 in a research note on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. JPMorgan Chase & Co. started coverage on Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They issued an “overweight” rating and a $88.00 target price for the company. Royal Bank Of Canada upped their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Finally, B. Riley Financial upped their target price on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.80.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.